Taken together, these findings indicate that despite highly elevated CRAF activity, robust pathway suppression with dual node targeting is sufficient to prevent transmission of this activity to downstream pathway outputs leading to more potent and durable anti-tumor activity, particularly in the RAS mutant setting where CRAF plays a more prominent role in pathway reactivation. The gene discussed is RAF1; the disease is neoplasm.